Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Seagen Inc.
SGN-CD19B will be given to patients at increasing doses every 28 days (or on an alternative dosing schedule of every 42 days).
Individual expansion cohorts of up to approximately 20 patients will be opened at dose levels selected by the Safety Monitoring Committee based on the aggregate known safety and activity data to further define the safety and antitumor activity in refractory and relapsed disease subgroups.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Relapsed, refractory, or progressive disease following at least 2 prior systemic therapies
Measurable disease
Eastern Cooperative Oncology Group status of 0 or 1
Adequate baseline renal and hepatic function
You may not be if
Prior treatment with CD19 directed agents unless CD19 expression is confirmed after completion of CD19-directed treatment
Known HIV, active hepatitis B or active hepatitis C infection
Prior allogeneic stem cell transplant
Inadequate lung function
Anticancer treatment within 4 weeks of study drug or 2 weeks if patient experienced disease progression on prior treatment
